Targeting carbonic anhydrase to treat diabetic retinopathy: emerging evidences and encouraging results.
Diabetic retinopathy (DR) is the leading cause of vision loss among working-age populations in developed countries. Current treatment options are limited to tight glycemic, blood pressure control and destructive laser surgery. Carbonic anhydrases (CAs) are a group of enzymes involving in the rapid conversion of carbon dioxide to bicarbonate and protons. Emerging evidences reveal CA inhibitors hold the promise for the treatment of DR. This article summarizes encouraging results from clinical and animal studies, and reviews the possible mechanisms.
Weiwei
Zhang
Z
Department of Endocrinology and Metabolism, HuaShan Hospital, Institute of Endocrinology and Diabetology, Shanghai Medical College, Fudan University, Shanghai 200040, China.
Hu
Renming
R
D000818:Animals; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use*; D002256:Carbonic Anhydrases / Q000187:drug effects* / Q000378:metabolism; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000201:enzymology; D005123:Eye / Q000201:enzymology*; D006801:Humans
D002257:Carbonic Anhydrase Inhibitors; D002256:Carbonic Anhydrases